Seer, Inc.与新加坡精准健康研究机构（Precision Health Research, Singapore）正式达成战略合作，双方将携手对1万份来自SG100k项目的精准生物样本开展深度、无偏的蛋白质组学分析。
此次合作旨在利用Seer先进的蛋白质组学技术平台，深入挖掘大规模人群样本中的蛋白质表达信息，为疾病机制研究和精准医疗发展提供关键数据支撑。SG100k作为新加坡重要的精准医学项目，其样本资源与Seer的创新技术结合，有望加速生物标志物发现和个性化治疗方案的开发。
通过这项合作，研究人员将能够获得前所未有的蛋白质组学数据深度和广度，推动对复杂疾病的分子层面理解，为未来健康干预策略奠定科学基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.